Reasons for Treatment (Tx) Discontinuation Among Hepatitis C (HCV) Patients Treated in Clinical Practice

被引：0

作者：

Yood, Marianne Ulcickas ^{[1
]}

Sapra, Sandhya ^{[2
]}

Oliveria, Susan A. ^{[1
]}

Casso, Deborah ^{[1
]}

Fu, An-Chen ^{[3
]}

L'Italien, Gilbert ^{[2
]}

机构：

[1] EpiSource, Newton, MA USA

[2] Bristol Myers Squibb Co, Plainsboro, NJ USA

[3] HealthCore, Wilmington, DE USA

来源：

HEPATOLOGY | 2012年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1746

引用

页码：1005A / 1005A

页数：1

共 50 条

[21] Impact of Age on Safety and Treatment Response in Patients with Hepatitis C (HCV) Treated With Boceprevir or Telaprevir [J].

Aronsohn, Andrew ;

Stainbrook, Tuesdae ;

Mohanty, Smruti ;

Mubarak, Abdullah ;

Spivey, James ;

Pandya, Prashant K. ;

Stewart, Thomas ;

Fried, Michael W. ;

Jacobson, Ira M. .

HEPATOLOGY, 2013, 58 :218A-218A

[22] The impact of antiretroviral treatment on the clinical course of hepatitis C in patients coinfected with HIV and HCV [J].

Bakowska, E ;

Gizinska, J ;

Podlasin, R ;

Jagodzinska-Hamann, L ;

Horban, A .

AIDS, 1998, 12 :S88-S88

[23] Molecular Evolution of Hepatitis C Virus (HCV) and Clinical Outcome in Patients with Hepatitis C [J].

Farci, Patrizia ;

Wollenberg, Kurt ;

Alter, Harvey J. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 :68-68

[24] Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice [J].

Marniquet, M. -E. ;

Seneschal, J. ;

Darrigade, A. -S. ;

Staumont-Salle, D. ;

Jachiet, M. ;

Nosbaum, A. ;

Tauber, M. ;

Abasq, C. ;

Ferrier Le Bouedec, M. -C. ;

Droitcourt, C. ;

Aubert, H. ;

Bernier, C. ;

Soria, A. ;

Raison-Peyron, N. ;

Tetart, F. ;

Aubin, F. ;

Viguier, M. ;

Valois, A. ;

Kupfer-Bessaguet, I. ;

Goronflot, T. ;

Barbarot, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) :733-735

[25] Medical reasons for dose adjustment and/or discontinuation of mitoxantrone in clinical practice [J].

Annette, Wundes ;

Kraft, George ;

Bowen, James ;

Gooley, Ted ;

Nash, Richard .

NEUROLOGY, 2008, 70 (11) :A94-A94

[26] Hepatitis C (HCV) Treatment Progress and SVR of Combination Therapy in Practice [J].

El-Hamdi, Nadia ;

Chen, Frankie ;

Cloyd, Aya ;

Alam, Imtiaz .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 :S673-S673

[27] Effectiveness of antiviral therapy in patients with chronic hepatitis C treated in daily clinical practice [J].

Goulis, John ;

Manolakopoulos, Spilios ;

Savvidou, Savvoula ;

Tsekoura, Panagiota ;

Papatheodoridis, George V. ;

Triantos, Christos ;

Anagnostou, Olga ;

Chrysanthos, Nikolaos ;

Thomopoulos, Konstantinos ;

Nikolopoulou, Vasiliki ;

Archimandritis, Athanasios ;

Chrysagis, Dimitrios ;

Tzourmakliotis, Dimitrios ;

Arvanitakis, Constantin .

HEPATOLOGY, 2006, 44 (04) :339A-339A

[28] An interdisciplinary team approach to hepatitis C evaluation and treatment: assessing the impact of clinical pharmacist involvement on HCV clinical practice and treatment. [J].

Bagwell, Autumn D. ;

Chastain, Cody .

PHARMACOTHERAPY, 2016, 36 (12) :E289-E289

[29] QUANTITATION OF HEPATITIS-C VIRUS (HCV) IN PATIENTS TREATED WITH INTERFERON [J].

AHMED, MM ;

MARTIN, BAB ;

ELIAS, E ;

HARRISON, RF ;

ODONNELL, K ;

SHAW, JC ;

MUTIMER, DJ .

GASTROENTEROLOGY, 1995, 108 (04) :A1023-A1023

[30] Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication [J].

Beste, Lauren A. ;

Ioannou, George N. ;

Larson, Meaghan S. ;

Chapko, Michael ;

Dominitz, Jason A. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (11) :972-978

← 1 2 3 4 5 →